Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet age-related diabetic macular edema (DME), retinal vein occlusion (RVO), and degeneration (AMD), and its capability to reduce treatment frequency. 

Notable studies presented at ARVO 2025 include:

FARETINA-nAMD and FARETINA-DME: With over 23,000 wet AMD and 5,400 DME patients, the FARETINA studies are the largest real-world analyses of Vabysmo to date, with 2-year real-world data confirming sustained vision improvements and significant reductions in retinal swelling for both wet AMD and DME.

  • Treatment-naïve patients experienced vision gains, while those previously on anti-VEGF therapy maintained stability.

  • FARETINA-nAMD and FARETINA-DME data show that patients required fewer Vabysmo injections over time, reducing treatment burden while maintaining or improving their vision.

BALATON/COMINO: New post hoc findings showed patients with RVO who achieved early resolution of macular blood vessel leakage were significantly more likely to maintain extended dosing intervals of every 3 to 4 months, reducing the need for more frequent injections.

  • Patients with minimal macular leakage at week 24 had more than twice the odds of achieving extended dosing intervals at week 68 compared to those with greater macular leakage. 

  • A greater proportion of patients treated with Vabysmo achieved absence of macular leakage at week 24 compared to aflibercept.

YOSEMITE/RHINE post hoc UWFA analysis: In the largest ultra-widefield fluorescein angiography (UWFA) analysis completed for a phase 3 trial, 415 patients treated with Vabysmo showed significantly greater reductions in blood vessel leakage and microaneurysm count compared to aflibercept 2 mg after 16 weeks.

  • Results suggest that dual Ang-2/VEGF-A pathway inhibition with Vabysmo may enhance vascular stability and potentially slow the course of DME.

Indirect Comparison of the Relative Effectiveness of Vabysmo vs Aflibercept 8 mg in DME and Wet AMD: A network meta-analysis indirectly comparing Vabysmo to aflibercept in DME and wet AMD found that Vabysmo led to greater reductions in central subfield thickness than both standard and high-dose aflibercept – while also delivering similar vision gains at 12 weeks.